Tamoxifen and Prevention of Breast Cancer

Bissett, D. , Davis, J.A. , and George, W.D. "Gynecological monitoring during tamoxifen therapy." Lancet 344:1244.

Bitman, J. , Cecil, H.C. , Harris, S.J. , and Fries, G.F. (1968). "Estrogenic activity of o.p-DDT in the mammalian uterus and avian oviduct." Science 162:371-372.

Breast Cancer Trials Committee (Bctc) (1987 ). "Adjuvant tamoxifen in the management of operable breast cancer." Lancet 2:171-175.

Brown, D. (1995). "Study backs 5-year limit on breast cancer drug ." Washington Post, December 1, 1995. p. A-28,

Bulger, W.H. , Muccitelli, R.M. , and Kupfer, D. (1978). "Studies on the induction of rat uterine ornithine decarboxylase by DDT analogs. II. Kinetic characteristics of ornithene carboxylase induced by DDT analogs and estradiol." Pestic. Biochem. Physiol . 8(3):263-270.

BUREAU NATIONAL AFFAIRS (BNA) (1996). May 14, 1996. 92A-4.

California Environmental Protection Agency (Cepa) (1995a). Evidence of the Carcinogenicity of Tamoxifen. Reproductive and Cancer Assessment Section Office of Environmental Health Assessment. March 1995. 39 pp.

California Environmental Protection Agency (Cepa) (1995b). Public Forum on Tamoxifen Comments 12/4/1995 , Office of Environmental Health Hazard Assessment, Science Advisory Board, 601 North 7th Street, Sacramento. CA 94234-7370.

California Environmental Protection Agency (Cepa) (1996). Chemicals Known to the State to Cause Cancer or Reproductive Toxicity. Office of Environmental Health Hazard Assessment, Safe Drinking Water and Toxic Enforcement Act of 1996. Listed September 1, 1996, p. 6 of the Revised list of May 1,1997.

Cohen, J. (1994). "Clinical trial monitoring: Hit or miss?" Science 264:1534-1537.

Cohen, I. , Altara, M.M. , Tepper, R. , Cordoba, M. , Figer, A. , Zalel, Y. , Dror, Y. , and Beyth, Y. (1997). "Different coexisting endometrial histological features in asymptomatic postmenopausal breast cancer patient treated with tamoxifen." Gynecol. Obstet. Investig. 43:60-63.

Cole, R. (1994). "Banana is latest food with biotech upgrade." Kalamazoo Gazette. July 9,1994. p. A-8.

Cunha, G.R. , Taguchi, O. , and Namikawa, R. (1987). "Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing female tract." Human Pathol. 18:1132-1143.

Danielian, PJ , White, R. , Hoare, S.A. , Fawell, S.B. , and Parker, M.G. (1993). "Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen." Molec. Endocrinol. 7:232-240.

Degregono, M.W. (1992). "Is tamoxifen chemoprevention worth the risk in healthy women?" J. NIH Res. 4:84-872.

Evans, N. (1996). "Tamoxifen Update: Debunking a wonder drug" Breast Cancer Action, Newsletter #35, April 1996. p.1.

Exacoustos, C. , Zupi, E. , Cangi, B. , Chiaretti, M. , Ardini, D. , and Romanini, C. (1995). "Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: An ultrasound, color flow Doppler, hysteroscopic and histological study." Ultrasound Obstet. Gynecol. 6:435-442.

Fendl, K.C. and Zimniski, SJ (1992). "Role of tamoxifen in induction of hormone-independent rat mammary tumors." Cancer Res. 52:235-237.

Fentiman, I.S. (1986). "Tamoxifen and mastalgia." Drugs 32:477-480.

Firshein, J. (1997). "Drug firm buys up chain of US cancer clinics ." Lancet 349:1230.

Fisher, B. (1992). "Consent to act as a participant in a clinical trial." University of Pittsburgh. January 1, 1992. pp. 7.

Fisher, B. , Costantino, J.P. , Redmond, C.K. , et al. (1994a). "Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NASBP) B-14. J. Nat. Cancer Inst. 86:527-537.

Fisher, B. , Constantino, J.P. , Redmond, C.K. , Fisher, E.R. , Wickersham, D.L. , and Cronin, W.M. (1994b). "Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National surgical adjuvant breast and bowel projects (NSABP) B-14:' J. Nat. Cancer Inst. 86:527-537.

Fisher, B. ,et al. (1996a). "Five versus more than five ycars of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors." J. Nat. Cancer Inst. 99(21): 1529-1542.

Fornander, T. , Rutquist, L.E. , Cedarmark, B. , and Glas, U. (1989). "Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers." Lancet 1:117-120.

Fugh-Berman, A. , Pearson, C. , and Rennie, S. (1991). Proposed Tamoxifen Prevention Trial Food and Drug Administration Oncological Drugs Advisory Committee. July 2, 1991. pp. 9.

Fugh-Berman, A. and Epstein, S. (1992). "Tamoxifen: Disease prevention or disease substitution ." Lancet 340:1143-1147.

Furr, B.J.A. and Jordan, V.C. (1984). "The pharmacology and clinical uses of tamoxifen ." Pharmacol. Therapeut. 25:127-205.

Gotfredson, A. , Christiansen, C. , and Palshof, T. (1984). "The effect of tamoxifen on bone mineral content in premenopausal women with breast cancer." Cancer 53:853-857.

Hardell, L. (1988). "Tamoxifen as a risk factor for carcinoma of the corpus uteri." Lancet 2:563.

Harper, M.J.K. and Walpole, A.L. (1966). "Contrasting endocrine activities of cis and trans isomers in a scries of substituted triphenylethylenes." Nature 21:87.

Harper, M.J.K. and Walpole,A.L. (1967). "Mode of action of ICI 46,474 in preventing implantation in rats" J. Endocrinol. 37:83-92.

Heinrichs, W.L. , Geller, R.J. , Bakke, J.L. , and Lawrence N.L. ( 1971). "DDT administered to neonatal rats induces persistent estrus syndrome." Science 173(997):642-643.

Herbst, A.L. and Scully, R.E. (1970). "Adenocarcinoma of the vagina in adolescence." Cancer 25:745-757.

Hilzenrath, D.S. (1994). "Drugmaker to enter care field." Washington Post. December 23, 1994. p. B-2.

Jaiyesimi, I.A. , Buzdar,A.U. , Decker, D.A. , and Hortobagyi, G.N. (1995). "Use of tamoxifen for breast cancer: Twenty-eight year later." J. Clin. Oncol. 13(2):513-529.

Jonat, W. and Maass, H. (1987). "The present status of the adjuvant endocrine treatment." J. Steroid Biochem. 27:499-502.

Jordan, V.C. , Dix, C.J. , and Naylor, K.E. (1978). "Nonsteroidal antiestrogens: Their biological effects and potential mechanisms of action." J. Toxicol. Environ. Health. 4 (2-3):363-390.

Jordan, V.C. , Allen, K.E. , and Dix, CJ (1980). "Pharmacology of tamoxifen in laboratory animals ." Cancer Treatment Reports 64(6-7):745-759.

Jordan, V.C. and Murphy, C.S. (1990). "Antiestrogens as antitumor agents." Endocr. Pharmacol. Endocr. Rev. 11:578-610.

Kedar, R.P. , Bourne, T.H. , Powles, T.J. , Collins, W.P. , Ashley,S.E. , Cosgrove, D.O. , and Campbell, S. (1994). "Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial." Lancet 343:1318-1321.

Kristensen, B. , Ejlertsen, B. , Mouridsen, H.T. , Andersen, K.W. , and Lauritzen, J.B. (1996). "Femoral fractures in postmenopausal breast cancer patients treated with adjuvant tamoxifen." Breast Cancer Res. Treatment 39:321-326.

Lear, L. and Carson, R. (1997). Witness for Nature, Henry Holt and Co., New York, NY. pp.478-479.

Luster, M.I. Faith, R.E. , Mclachlan.J.A. , and Clark, G.C. (1979). "Effect of in utero exposure to diethylstilbestrol on the immune response in mice." Toxicol. Appl. Pharmacol. 47(2):279-285.

Marshall, B. (1994). "Tamoxifen: Hanging in the balance." Science 264:1524-1527.

National Institutes Of Health (Nih) (1998). "Cancer Research—Because lives depend on it" Press Release, April 6, 1998.

National Women'S Health Network (Nwhn) (1998 ). "What about prevention for the rest of us?" NWHN response to NCI announcement of "Good News." April 6, 1998 . Washington, DC. pp. 2.

Nease, R.F. and Ross, J.M. (1995). "The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in health women: An analysis of the tradeoffs ." Amer. J. Med. 99:180-189.

Nicholson, R.I. and Griffiths, K. (1980). "The biochemistry of tamoxifen action." Adv. Sex Hormone Res. 4:119-152.

Nomura,Y. , Miura, S. , Koyama, H. , Enomoto, K. , Kasumi, F. , Yamamoto H. , Kimura, M. , Tominaga, I. , Hona, H. , Morimoto, T. , and Tashiro, H. (1991). "Relative effect of steroid hormone receptors on the prognosis of patients with operable breast cancer." Cancer 69:153-164.

Nowak, R. (1994). "Problems in clinical trials go far beyond misconduct ." Science 264: 1538-1541.

Okie, S. (1998). "Tamoxifen lowers risk of breast cancer." Washington Post Health, April 7, 1998. p. 7.

Pavlidis, N.A. , Petris, C. , and Briasoulis, E. (1992). "Clear evidence that long-term, low-dose tamoxifen treatment can induce ocular toxicity." Cancer 69:2961-2964.

Pesticide Action Network (Pan) (1995). Global Pesticide Campaigner PAN, San Francisco, CA. 5(3):19

PHYSICIANS' DESK REFERENCE (1993). Medical Economics Co, Inc. Montvale, NJ. pp. 1126-1128.

Raloff, J. (1992). "Tamoxifen and informed consent/dissent." Sci. News. 142:378-340.

Reaney, P. (1998). "UK doctors criticize US handling of cancer study "April 7, 1998 Reuters, London, UK.

Rock,A. ( 1995). "The breast cancer experiment." Ladies Home Journal. February, 1995. pp. 144-151.

Sherman, J.D. (1994). Chemical Exposure and Disease. Princeton Scientific Publishing Co., Inc. Princeton, NJ. pp. 33, 46, 68, 122-123, 173-188.

Shimikin,M.B. and Grady, H.G. (1941). "Carcinogenic potency of stilbestrol and estrone in strain C3H mice." J. Nat. Cancer Inst. 1:119-128.

Schroeter,L.W. (1998). Personal communication April 10, 1998.

Seachrist, L. (1994). "Animal tests take back seat to clinical data ." Science 264:1525.

Shabad, L.M. , Kolesnichenko, T.A. , and Nikonova,T.V. (1973). "Transplacental and combined long-term effect of DDT in five generations of A-strain mice." Intl. J. Cancer 11(3):688-693.

Tate, A.C. , Lieberman, M.E. , and Jordan, V.C. (1984). "The inhibition of prolactin synthesis in GH3 rat pituitary tumor cells by monohydroxytamoxifen in associated with changes in the properties of the estrogen receptor." J. Steroid Biochem . 20:391-395.

Tewari, K. , Bonebrake, R.G. , Asrat, T. , and Shanberg, A.M. (1997). "Ambiguous genitalia in infant exposed to tamoxifen in utero." Lancet 350:183.

Turusov, V.S. , Day, N.B. , Tomatis, L. , Gati, E. , and Charles, R.T. (1973). "Tumors in CF-a mice exposed for six generations to DDT." J. Nat. Cancer Inst. 51(3):983-997.

U.S. Environmental Protection Agency (Usepa) ( 1975). Substitute Chemical Program, Initial Scientific and Minieconomic Review of Captan, EPA-540/1-75-012, pp. 173.

U.S. Environmental Protection Agency (Usepa) ( 1977). RPAR (Rebuttable Presumption Against Registration) for Captan, August 10, 1977.

U.S. Food And Drug Administration (Usfda) ( 1994). Bulletin. page 3. May 1994.

Van Leeuwen, F.E. , Benraadt, J. , Coebergh, J.W.W. , Kiemeney, L.A.L.M. , Gimbrere, C.H.F. , Otter, R. , Schouten, L.J. , Damhuis, R.A.M. , Bontenbal M. , Diepenhorst, F.W. , Van Den Belt-Dusebout,A.W. , and Van Tinteren, H. (1994). "Risk of endometrial cancer after tamoxifen treatment of breast cancer." Lancet 343:448-452.

Vorheer, H. , Messer, R.H. , Vorheer, U.F. , Jordan, S.W. , and Kornfeld, M. (1979). "Teratogenesis and carcinogenesis in rat offspring after transplacental and transmammary exposure to diethylstilbestrol." Biochem. Pharmacol. 28(12):1864-1877.

Wassermann, M. , Nogueira, D.P. , Tomatis, L. , Mirra,A.P. , Shibata, H. , Arie, G. , Cucos, S. , and Wassermann, D. (1976). "Organochlorine compounds in neoplastic and adjacent apparently normal breast tissue:' Bull. Environ. Contam. Toxicol. 15(4):478-484.

Wolff, M. (1993). "Blood levels of organochlorine residues and risk of breast cancer." J. Nat. Cancer Inst. 85:648-652.

Zeneca Pharmaceuticals Group (Zpg) (1993). Annual Report and Accountants pp. 68.

Zeneca Pharmaceuticals Group (Zpg) (1994a). "Dear Doctor" letter from Zeneca Pharmaceuticals Group . 3 pages, April 8, 1994.

Zeneca Pharmaceuticals Group (Zpg) (1994b). "Dear Doctor" letter from Zeneca Pharmaceuticals Group . 3 pages, April 8, 1994.